Patient Registry of Blind Subjects With Sleep-related Problems

NCT01195558 · tracked via the Priya Life Science USA tracker

Sponsor

Vanda Pharmaceuticals

Phase

Observational

Started

2010-04

Last updated

2020-06-24

Condition(s) studied

Sleep-wake Disorder in Blind Individuals

Investigational drug(s) / intervention(s)

Data collection on blindness and sleep problems

Data collection on blindness and sleep problems: Data related to degree of vision impairment and sleep problems is collected through a phone or web survey

Study summary

Non-24-hour sleep-wake disorder (Non-24) is a condition experienced primarily by totally blind individuals that results in abnormal night sleep patterns and chronic daytime sleepiness. This is a research protocol to develop a patient registry of subjects who may suffer from Non-24 and who are blind. Subjects participate in the study through a phone survey. This registry will be used to better understand, sleep related problems in blind individuals, including the investigation of a potential treatment, recruitment for future clinical studies, and to provide a forum for raising awareness about Non-24. The survey consists of questions regarding the degree of vision impairment and sleep problems that the subjects may be experiencing.

Eligibility

Sex

ALL

Min age

—

Max age

—

Healthy volunteers

Inclusion Criteria: 1. Subjects or legal guardians must be at least 18 years of age to participate in the telephone survey. Parents or legal guardians may represent children from 0 through 17 years who meet the following criteria. 2. Subjects must be blind. 3. Subjects must have some self-described problem with sleep or daytime sleepiness.

Primary outcome measure(s)

Number of blind participants — ongoing

Trial sites (1)

Facility	City	Region	Status
Vanda Pharmaceuticals	Washington D.C.	District of Columbia	Recruiting

More Vanda Pharmaceuticals trials in the USA

Safety, Tolerability and Efficacy of Trichostatin A in Patients With Mild to Severe Onychomycosis Active, not recruiting

Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies Recruiting

Evaluating the Effects of Tasimelteon vs. Placebo in Treating Pediatric Insomnia Recruiting

An Eight-Week Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry Eye Recruiting

Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness Active, not recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT01195558 on ClinicalTrials.gov ↗ ← All trials in the USA